The phase 1 study tested autogene cevumeran (BNT122, RO7198457), a therapeutic mRNA cancer vaccine developed and researched through a collaboration between BioNTech, an immunotherapy company, and ...
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and inclusion (D&I) page undergoes construction. “The page that is under ...
This approval marks another significant step forward,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “The Evrysdi tablet combines ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for ...
SOUTH SAN FRANCISCO, Calif., February 12, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration ...
Credit: MirageC via Getty Images. Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market ...
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness – Susvimo is the first and only continuous delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback